Table of Contents
For healthcare companies, “when to finance” is not a simple financial question.
A company may initiate financing when it has ample cash on its books, or it may not be suitable for financing even when its cash flow is tight. What really needs to be judged is: whether the company has formed a sufficiently clear investment logic, and whether the new funds, once injected, can help the company complete a next-stage milestone that can significantly enhance its value.
Therefore, to determine whether a healthcare company is suitable for financing, you can start from six aspects:
- Has the company clearly defined its development goals for the next stage?
- Does it have a core value that can be verified by investors?
- Is there a clear purpose for the financing funds?
- What are the key milestones required for the next round of financing?
- Does the company’s current cash flow and time window allow for sufficient preparation?
- Can the current financing improve, rather than weaken, the company’s future capital options?
In short, the suitable time for financing is usually not “when you are most in need of money,” but “when the company has formed a phased value, and the funds can help the company complete the next value leap.”
I. First, Answer: Why Does the Company Need Financing Now?
Before financing, the company should first answer a very specific question:
If a new sum of money is obtained now, what will it help the company accomplish in the next 12-24 months?
This question is more important than “how much money do we need.”
For healthcare companies, the use of funds may include:
- Advancing new drug R&D and clinical development;
- Completing key clinical trials;
- Promoting medical device registration and commercialization;
- Building production and supply chain capabilities;
- Expanding sales and commercialization teams;
- Expanding into new indications or product lines;
- Carrying out licensing, BD, or strategic cooperation;
- Conducting industrial M&A;
- Expanding into overseas markets;
- Supplementing working capital.
If the company can only answer “we need funds to support the company’s development” without further explaining which specific milestones the funds will correspond to, then the financing preparation is usually not sufficient.
Conversely, if the company can clearly state:
This round of financing will support the company in completing three key milestones, A, B, and C, and will enable the company to enter the next stage of commercialization, clinical, registration, or industrial cooperation.
The financing story will be more complete.
II. The First Indicator for Judging the Timing of Financing: Is it Close to an Important Value Milestone?
For healthcare companies, the timing of financing is often highly correlated with business milestones.
The milestones of different companies can be completely different.
Innovative Drug Companies
The value of an innovative drug company is usually related to factors such as R&D progress, clinical data, indications, competitive landscape, intellectual property, and commercialization potential.
For example:
- Completing candidate drug screening;
- Completing preclinical studies;
- Obtaining clinical trial-related permits;
- Completing Phase I;
- Obtaining Phase II data;
- Completing key clinical studies;
- Obtaining marketing approval;
- Building commercialization capabilities.
The FDA’s public drug development process also shows that drug development proceeds from discovery and development, preclinical research to clinical research, and then to regulatory review and post-marketing stages. Clinical research itself is further divided into different phases, each undertaking different safety and efficacy verification tasks.
Therefore, for innovative drug companies, the timing of financing needs to be combined with the next stage of R&D milestones, and cannot be judged solely based on the cash balance.
Medical Device Companies
The financing nodes for medical device companies may be related to:
- Product finalization;
- Prototype completion;
- Clinical validation;
- Registration application;
- Registration approval;
- GMP and production capacity building;
- Commercialization ramp-up;
- Overseas registration;
- Channel expansion
and other stages.
The regulatory pathway for medical devices will vary according to the product’s risk level and applicable regulatory requirements, so the financing plan should also be combined with the specific product’s development and registration pathway.
Healthcare Service and Health Tech Companies
For companies in healthcare services, digital health, AI + healthcare, etc., value milestones may be more manifested as:
- Growth in user numbers;
- Increase in hospital or institutional customers;
- Revenue growth;
- Increase in renewal rates;
- Improvement in unit economics;
- Improvement in gross margin;
- Expansion of service network;
- Validation of business model;
- Improvement in profitability.
Therefore, the timing of financing should be designed around the company’s own value creation path, rather than simply being determined by financing rounds.
III. The Second Indicator: Does the Company Already Have a “Verifiable Financing Logic”?
Investors not only judge how much the company is worth today, but also:
Why might the company be more valuable in the future?
Therefore, an effective financing logic usually needs to answer four questions.
1. What problem does the company solve?
Who are the patients, hospitals, doctors, consumers, or industrial customers that the company serves?
2. Why can the company solve this problem?
What are the characteristics of the company’s technology, products, channels, business model, or industrial resources?
3. To what extent has it been verified so far?
The company needs to prove its development progress with actual data, such as:
- Clinical data;
- Registration progress;
- Product revenue;
- Number of customers;
- Partners;
- Orders;
- Renewal rate;
- Gross margin;
- Market coverage;
- Patents and intellectual property;
- Industrial cooperation.
4. What changes will the next sum of money bring?
This is the most important part of the financing logic.
If CNY 10 million can only let the company “survive for another year,” its capital significance is completely different from CNY 10 million that can help the company complete a key clinical milestone, obtain registration, achieve a commercial breakthrough, or establish an important industrial cooperation.
Therefore, the financing materials should not only contain “what has been done in the past,” but also clearly state:
Financing → Capital Investment → Key Milestones → Change in Company Value.
IV. The Third Indicator: Is the Company Ready to Accept the Scrutiny of the Capital Market?
Financing is not only about obtaining funds, but also a systematic corporate check-up.
Investors will typically understand the company from multiple dimensions, including:
- Equity structure;
- Founding team;
- Core technology;
- Intellectual property;
- Product pipeline;
- Clinical or registration progress;
- Business model;
- Market size;
- Competitive landscape;
- Financial situation;
- Cash flow;
- Related-party transactions;
- Historical financing;
- Future capital needs.
Therefore, if there are a large number of unresolved issues in the company, hastily launching financing may consume management’s time and reduce financing efficiency.
This is especially true for healthcare companies, where technical and product information is often complex.
For example, an innovative drug company needs to systematically organize its R&D pipeline, clinical data, intellectual property, and subsequent development plans; a medical device company needs to establish a complete information system based on its products, registration, clinical, and production and commercialization situation.
The purpose of financing preparation is not to package the company more beautifully, but to allow investors to understand the company’s true value more quickly.
V. The Fourth Indicator: How Long Can the Cash Last?
Cash flow is still an important factor in judging the timing of financing, but it should not be the only factor.
Companies need to establish a funding plan that covers at least the next 12-24 months, focusing on answering:
- What is the current cash balance?
- What are the monthly fixed cash expenditures?
- What is the R&D investment?
- What is the commercialization investment?
- What is the expected revenue?
- What are the major one-time expenditures in the future?
- How much funding is needed for the next stage?
- How long might it take from the start of financing to the receipt of funds?
This is particularly important for R&D-based healthcare companies.
If a company waits until its cash is about to run out to start financing, the management may be forced to accept a shorter negotiation period and more limited transaction options.
Therefore, a more reasonable approach is usually:
To start preparing for financing when the cash flow is still manageable and the company still has time to choose a financing plan.
VI. The Fifth Indicator: Can This Round of Financing Take the Company to the “Next Level”?
One of the most common problems in corporate financing is the mismatch between the financing amount and the company’s development stage.
For example:
The company plans to raise CNY 50 million, but the funds can only maintain daily operations, with no clear phased goals.
Then in the next round of financing, investors may still face the same question:
After the company received the last round of funding, what changes have actually occurred?
Therefore, when designing a financing plan, you can think backwards:
If financing is needed in the next 18 months, what state does the company want to be in after 18 months?
For example:
R&D-focused Company:
Financing → Complete key clinical stage → Obtain important data → Enhance asset value → Next round of financing or licensing deal
Medical Device Company:
Financing → Complete registration → Build commercialization team → Acquire customers → Achieve revenue growth → Next round of financing or industrial cooperation
Healthcare Service Company:
Financing → Expand service network → Improve revenue and operational efficiency → Improve unit economics → Achieve scaled growth
This is the so-called “milestone financing.”
VII. When is it Possibly “Not Suitable” to Finance Immediately?
Not all companies should immediately launch financing when they need funds.
The following situations are worth careful consideration.
Situation 1: The Company’s Core Product Has Not Yet Formed a Clear Value Proposition
If the company is still in a very early exploration stage, and its core technology, product positioning, or business model are not yet clear, then financing may require high information communication costs.
At this time, the company can first complete key validations that can significantly reduce investor uncertainty.
Situation 2: The Use of Funds is Too Vague
If the company cannot clearly state what the funds will be used for, and what results these funds will produce, then the financing plan is difficult to form a complete investment logic.
Situation 3: The Company is About to Reach an Important Value Inflection Point
If a company is very close to an important clinical, registration, product, or commercialization milestone, it can evaluate whether it is necessary to complete the milestone first before launching financing.
There is no fixed answer that applies to all companies here.
The key is to compare:
The value of the funds obtained from early financing
with
The potential increase in corporate value after completing the milestone
Situation 4: Equity Structure and Historical Issues Have Not Been Sorted Out
If the company has complex equity arrangements, historical financing documents, related-party transactions, intellectual property ownership, or other issues that need to be explained, these should be sorted out first.
The exposure of these issues during the investor due diligence stage may lead to a longer transaction cycle.
VIII. How Should the Financing Amount be Determined?
The financing amount should not be simply determined by “how much investors are willing to invest.”
A more reasonable method is to reverse-calculate from the company’s future development plan.
A simple framework can be used:
Financing Need = Next Stage Operating and R&D Funding Needs + Transaction and Financing Costs + Safety Cash Reserve - Estimated Operating Cash Flow during the Period
For example, if the company plans to complete the following in the next 18 months:
- A key R&D milestone;
- A product registration milestone;
- A round of commercialization investment;
- Expansion of the core team;
Then, it should first calculate how much funding is needed to achieve these goals, and then determine the financing scale based on the company’s own cash flow.
A financing amount designed in this way is more easily linked directly to the company’s development plan.
IX. More Financing Rounds are Not Always Better
The core purpose of corporate financing is not to continuously complete “the next round of financing.”
What is really important is:
Whether the company has created new value after each round of capital injection.
One round of financing should correspond to a clear development stage as much as possible.
For example:
Early-Stage Capital
Mainly solves product and technology validation problems.
↓
Growth Capital
Mainly solves clinical, registration, business model, and market expansion problems.
↓
Scale-Up Capital
Mainly solves commercialization expansion, production capacity, channel, and industrial integration problems.
↓
Strategic Capital
May further support industrial synergy, M&A, licensing, internationalization, or capital market exit.
Therefore, companies should consider their future capital path in advance, rather than treating each financing as an independent event.
X. What Should a Company Prepare Before Financing?
If a company decides to launch financing, it is recommended to prepare at least the following six types of materials.
1. Company Positioning
Explain in one sentence:
Who we are, what problem we solve, and who we serve.
2. Products and Technology
Explain the core products, technological advantages, intellectual property, and R&D progress.
3. Market and Competition
Explain the target market, competitive environment, company positioning, and future growth potential.
4. Business and Finance
Including revenue, gross profit, cash flow, customers, orders, commercialization plans, etc.
5. Capital History
Including historical financing, equity structure, major shareholders, and future capital plans.
6. This Round of Financing Plan
At a minimum, it needs to be clear:
- Financing scale;
- Use of funds;
- Estimated financing stage;
- Post-investment development plan;
- Key milestones for the next stage;
- Future capital path.
The clearer these contents are, the easier it is for investors to quickly understand the company.
XI. A Simple “Financing Timing Judgment Table”
Companies can use the following questions for internal self-examination:
| Judgment Question | What to Pay Attention To |
|---|---|
| Why finance now? | Is there a clear strategic funding need? |
| What to do after financing? | Is there a specific use of funds? |
| What state to achieve in 18 months? | Are there clear milestones? |
| What value proof is there now? | Technology, clinical, registration, customer, or revenue |
| How long can the cash last? | Is there enough time to complete the financing? |
| Is the equity structure clear? | Are historical financing and shareholder relations standardized? |
| Is the financial data complete? | Can revenue, cost, and cash flow be explained? |
| Is the due diligence material ready? | Are the legal, financial, and business materials complete? |
| What will the next round of financing rely on? | Has the next-stage capital path been considered? |
If most of the questions can be answered clearly and verifiably, the company usually has a good foundation for financing preparation.
XII. What Financing Should Really Solve is “Next-Stage Growth”
For healthcare companies, financing is not the end of corporate development, but a capital tool that connects two development stages.
Therefore, instead of asking:
“Can we finance now?”
It is better to ask:
“If we finance now, can the funds help us complete a key stage that is sufficient to change the company’s value?”
If the answer is yes, then financing is not just about solving cash needs, but may become an important tool for the company’s R&D, commercialization, industrial cooperation, and strategic expansion.
Conversely, if the company currently lacks a clear value proposition, use of funds, or next-stage milestones, then it may be more important to complete internal preparations first, and then choose a suitable financing window.
For healthcare companies, the ideal timing for financing usually needs to meet three conditions simultaneously:
A clear funding need + a verifiable phased value + a clear next-stage milestone.
These three conditions together form the basis for financing decisions.
T-Capital’s View on Healthcare Company Financing
Healthcare company financing is not a simple capital connection, but a match between the company’s development stage, product value, industrial resources, and capital strategy.
T-Capital has a long-term focus on capital transactions in the healthcare field, providing capital advisory services such as private financing, M&A and sale, License & BD, strategic cooperation, and cross-border transactions for companies.
For healthcare companies preparing for financing, the important work before financing usually includes:
- Sorting out the company’s development stage;
- Clarifying the financing objectives;
- Sorting out the core value and investment logic;
- Designing a capital use plan;
- Clarifying the next-stage value milestones;
- Screening for matching capital and industrial resources;
- Promoting financing negotiations and transaction execution.
If a company is considering financing, it can start with the three questions of “why finance now, what to complete after financing, and how to enhance value in the next stage.”
T-Capital can also further discuss financing strategies, capital structures, and potential transaction paths based on the specific development stage of the company.
Disclaimer: The judgment framework in this article belongs to general capital transaction and corporate strategy analysis, and does not constitute financing, investment, or legal advice for specific companies. The timing of financing for different companies needs to be analyzed specifically in combination with their business stage, financial situation, regulatory progress, capital structure, and transaction environment.